Authors


Gabriela S. Hobbs, MD

Latest:

Key Takeaways: Optimal Use of JAK Inhibitors in MF and Future Directions in Care

Panelists share key takeaways on management strategies in myelofibrosis and hope for future evolutions in the treatment paradigm.


Patricia Fischer, Research Nurse, Memorial Sloan Kettering Cancer Center

Latest:

Value of Collaboration in Managing Patients With Metastatic RCC

Closing out their discussion on the management of metastatic renal cell carcinoma, panelists highlight the value of collaborative care in improving patient outcomes.


Michael Szarek, PhD

Latest:

Michael Szarek, PhD, on Research Areas of Focus for Tivozanib in RCC

The expert from SUNY Downstate Medical Center spoke about areas of research for renal cell carcinoma which he believes deserve further attention.


Dana Chase, MD

Latest:

Oncology On-The-Go Podcast: SGO 2023 Recap

Experts from UCLA Health discuss key data presented at The Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer and how they may apply to clinical practice.


Peter Forsberg, MD

Latest:

Looking Forward: Advice for Clinicians and Discussing Unmet Needs in the R/R MM Landscape

Dr. Joshua Richter and Dr. Peter Forsberg close their discission with thoughtful advice for clinicians regarding the current and future treatment of patients with R/R MM.


Jonathan Kaufman, MD

Latest:

Exploring CAR-T Therapy in Early Lines of Relapsed/Refractory Multiple Myeloma

Panelists discuss the data surrounding the use of CAR-T therapy in earlier lines of treatment for relapsed/refractory multiple myeloma (R/R MM), including findings from the cilta-cel (Popat R, et al. ASH 2024 No. 1032; Mateos MV, et al. IMS 2024 No. OA-65), and Idel-cel (Ailawadhi S, et al. Blood 2024) studies, and share their thoughts on the implications of these results.



Laila A. Gharzai, MD

Latest:

Face-Off: Award Presentation Ceremony

Following a spirited debate, Joshua K. Sabari, MD, presents the winning team with the coveted title of victors of this CancerNetwork® Face-Off event.


Mansoor Raza Mirza, MD

Latest:

Dostarlimab/Chemo Yields “Unprecedented” OS in dMMR Endometrial Cancer

Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.



Randy C. Miles, MD, MPH

Latest:

Oncology Peer Review On-The-Go: Routine Breast Cancer Screening in Average-Risk Women Younger Than 50 Years

CancerNetwork’s latest podcast episode features a conversation with Anath Ravi, PhD, of MOLLI Surgical and Randy Miles, MD, MPH, of Massachusetts General Hospital on the risks and benefits of breast cancer screening for average-risk women under the age of 50 years.





Michael J. Hall, MD, MS, FASCO

Latest:

Making Intervention Accessible for All Li-Fraumeni Syndrome Populations

Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.


Se Hoon Park, MD, PhD

Latest:

Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.


Eric Singhi, MD

Latest:

Treating Patients with SCLC with Driver Mutations

The Oncology Brothers and Eric Singhi, MD, provide clinical insights on the treatment of patients with small cell lung cancer with driver mutations.


Daniela Allende, MD

Latest:

Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer

Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.


Bhagirathbhai Dholaria, MBBS

Latest:

‘Future Is Bright’ With Bispecifics for Relapsed/Refractory Myeloma

An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.


Joseph Franz, MD

Latest:

Future Perspectives and Unmet Needs in Multiple Myeloma

The expert panel concludes their discussion by examining the unmet needs and future for the treatment landscape in multiple myeloma.


Peter C. Lucas, MD, PhD

Latest:

Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US

Ibrahim Halil Sahin, MD, and colleagues, explore, the CIRCULATE-US (NRG-GI008; NCT05174169) investigating postoperative ctDNA dynamics in early-stage colon cancer for treatment selection.


Narjust Florez, MD

Latest:

Face-Off: Award Presentations and Event Conclusion

Judy concludes the event and presents the awards.


Stacey A. Cohen, MD

Latest:

CLM in GALAXY: MRD Predicts Adjuvant Therapy Benefit and Prognosis

Panelists discuss how minimal residual disease (MRD) detection in patients with colorectal liver metastases (CLM) in the GALAXY study predicts both the benefit of adjuvant therapy and overall prognosis, potentially guiding more personalized treatment decisions.


Matthew Krebs, MB, PhD

Latest:

Matthew Krebs, MB, PhD, Reviews the Next Steps for Subcutaneous Amivantamab in Solid Tumors

Matthew Krebs, MB, PhD, spoke about how subcutaneous amivantamab can best be utilized in future clinical trials.


John T. Lafin, PhD

Latest:

Management of Testicular Germ Cell Tumor With Somatic-Type Malignancy

In this installment of Clinical Quandaries, Bendu Konneh, BS, and colleagues present a case of a 21-year-old male with a 4-month history of progressive swelling in the right testicle.



Judy C. Boughey, MD

Latest:

Lumpectomy Yields Clinically ‘Acceptably Low’ Recurrence Rates in Breast Cancer Subtype

Judy C. Boughey, MD, of Mayo Clinic in Rochester, Minnesota details the efficacy of breast-conserving surgery in patients with multiple ipsilateral breast cancer.


Esther Drill, DrPH

Latest:

Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab

Rituximab-subcutaneously is associated with significantly reduced chair time vs rituximab-intravenously in a US oncology setting. Widespread adoption would be expected to improve practice efficiency and patient access to care, and to reduce health care resource burden.


Suzanne Fanning, DO

Latest:

Future Directions in the Treatment of Multiple Myeloma

Drs Richter and Fanning discuss next steps and future directions in the management of patients with relapsed/refractory multiple myeloma.


Addison Taylor, MD, PhD

Latest:

Unusual Initial Presentation of Hepatocellular Carcinoma as a Clavicular Head Mass

Rohit Gupta, MD, et al review a case study of a 70-year-old man who presented with a head mass, and the final diagnosis was hepatocellular carcinoma.